irofulven has been researched along with Cancer of Stomach in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beale, P; Boyer, M; Chan, AT; Chung, HC; Clarke, S; Goh, BC; Ho, R; Jeung, HC; Lam, KC; Lim, R; Ma, B; Mo, FK; Ng, EK; Ong, SY; Rha, SY; Roh, JK; Soo, R; Yeo, W; Zee, B | 1 |
| Kashimoto, S; MacDonald, JR; Nakano, K; Sato, Y | 1 |
1 trial(s) available for irofulven and Cancer of Stomach
| Article | Year |
|---|---|
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Infusions, Intravenous; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Sesquiterpenes; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2007 |
1 other study(ies) available for irofulven and Cancer of Stomach
| Article | Year |
|---|---|
In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Humans; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Sesquiterpenes; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2001 |